Red Flags Detected
- Delisting (new) — Company faces potential delisting from Nasdaq if it fails to maintain $1.00 minimum bid price by November 30, 2026.
aTyr Pharma gets 180-day extension to regain Nasdaq compliance or face delisting
Filed June 8, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Nasdaq granted extension until Nov 30, 2026 to meet $1.00 minimum bid price requirement; company may use reverse stock split if needed to avoid delisting
Item 3.01 verify on EDGAR → -
medium
Stock must close at or above $1.00 for 10 consecutive business days (potentially 20 at Nasdaq's discretion) to regain compliance
Item 3.01 verify on EDGAR → -
high
Original deficiency notice received Dec 4, 2025 after stock traded below $1.00 for 30 consecutive days; first 180-day period expired June 2, 2026 without compliance
Item 3.01 verify on EDGAR →
1 more material change plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.
Partner
Trade ATYR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 8, 2026 8:41 PM